Andrew N. Schiff - 05 Jun 2025 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role: Director
Signature: /s/ Matthew Rothman, Attorney-in-Fact
Issuer symbol: ACRS
Transactions as of: 05 Jun 2025
Net transactions value: $0
Form type: 4
Filing time: 09 Jun 2025, 16:20:31 UTC
Previous filing: 13 Jun 2024
Next filing: 16 Jun 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
SCHIFF ANDREW N	Director	C/O ACLARIS THERAPEUTICS, INC., 701 LEE ROAD, SUITE 103, WAYNE	/s/ Matthew Rothman, Attorney-in-Fact	09 Jun 2025	0001172252

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ACRS	Common Stock	Options Exercise		+4,793	+52%		13,960	06 Jun 2025	Direct	F1
holding	ACRS	Common Stock						434,455	05 Jun 2025	By Aisling Capital IV LP	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ACRS	Stock Option (Right to Buy)	Award	$0	+42,350		$0.000000	42,350	05 Jun 2025	Common Stock	42,350	$1.56	Direct	F3, F4
transaction	ACRS	Restricted Stock Units	Award	$0	+11,580		$0.000000	11,580	05 Jun 2025	Common Stock	11,580		Direct	F1, F4, F5
transaction	ACRS	Restricted Stock Units	Options Exercise	$0	-4,793	-100%	$0.000000	0	06 Jun 2025	Common Stock	4,793		Direct	F1, F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F2	The reportable securities are owned directly by Aisling Capital IV, LP ("Aisling"), and held indirectly by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Schiff disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.
F3	The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 5, 2025, subject to the Reporting Person's Continuous Service (as defined in the Plan) through each such vesting date.
F4	This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy.
F5	The shares underlying these restricted stock units will vest in one installment on June 5, 2026, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date.
F6	The shares underlying these restricted stock units vested on June 6, 2025.